ESLA logo

ESLA
Estrella Biopharma Inc

330
Mkt Cap
$80.21M
Volume
21,479.00
52W High
$3.15
52W Low
$0.78
PE Ratio
-5.27
ESLA Fundamentals
Price
$1.81
Prev Close
$1.88
Open
$1.89
50D MA
$1.28
Beta
0.72
Avg. Volume
53,191.30
EPS (Annual)
-$0.3548
P/B
-6.89
$56.06
Loading...
Loading...
News
all
press releases
Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% - Here's Why
Estrella Immunopharma (NASDAQ:ESLA) Shares Up 26.5% - Here's What Happened...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·28d ago
News Placeholder
D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA)
D. Boral Capital reissued a "buy" rating and issued a $8.00 price target on shares of Estrella Immunopharma in a research report on Monday...
MarketBeat·2mo ago
News Placeholder
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR
Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·2mo ago
News Placeholder
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR
Estrella Immunopharma, Inc. (Nasdaq: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·3mo ago
News Placeholder
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune...
Business Wire·4mo ago
News Placeholder
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5%
Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 709,318 shares, an...
MarketBeat·4mo ago
News Placeholder
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - Here's Why
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - What's Next...
MarketBeat·4mo ago
News Placeholder
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·5mo ago
News Placeholder
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded Estrella Immunopharma to a "hold" rating in a research note on Saturday...
MarketBeat·5mo ago
<
1
2
...
>

Latest ESLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.